Analytics

Wednesday, January 24, 2018

Post #3530 M

Quote of the Day

All that is necessary for the triumph of evil is 
that good men do nothing.
Edmund Burke  

Tweet of the Day









DEAD WRONG: Unfair Equality Over Fair Inequality




Facebook Corner

I have a cousin who works for a major pharmaceutical. He was not happy with companies who decide to divest from neurological research/product development like Pfizer. He posted a leftist group using Pfizer as benefiting from the new tax law while cutting its program for Alzheimer's and Parkinson's. I snapped back on the absurd tie between tax reform and he quickly regretted posting the video and political claptrap, saying he didn't like Pfizer's  reducing opportunities for professionals like him and a fellow female colleague. Unfortunately, his friend had no issue ranting leftist BS at me. So I start with my response and then a post of my own, following up.

This is economic illiterate rubbish. Pfizer is not in the business of losing money on drugs that don't work. Using tired, ignorant rubbish like "trickle-down" economics is pathetic; the poor today have access to pharmaceutical products and vaccines, not made just for the 1%, never mind cellphones, transportation, appliances, etc. Coolidge's son died from complications of a foot blister a century ago, when the nation's best doctors couldn't help.



A cousin recently posted a leftist attack video on the recent tax reform law, somehow trying to absurly tie it to Pfizer's recent decision to leave the markets for Alzheimer's and Parkinson's. When I suggested that the decision was related to poor prospects in drug development, one of my cousin's economic illiterate colleagues mocked my inference of failing drugs and went on an anti-capitalist rant. Here's what 5 seconds of a Google search will tell you (Marketwatch):

Pfizer Inc. said Saturday it will stop trying to discover new drugs for Alzheimer’s disease and Parkinson’s disease, abandoning costly but futile efforts to find effective treatments for the disorders.
The restructuring won’t affect later-stage drug development for pain treatments Lyrica and tanezumab, or research into drugs for rare neurological diseases, Pfizer said.
The company plans to use the savings to fund drug R&D in other areas. “This was an exercise to reallocate [spending] across our portfolio, to focus on those areas where our pipeline, and our scientific expertise, is strongest,” it said. Like several peers, Pfizer PFE, +0.30% has invested heavily in developing treatments for Alzheimer’s and Parkinson’s because of the huge need, but met disappointment when once-promising compounds failed to work during testin
g

Political Cartoon



Courtesy of Henry Payne via Townhall


Musical Interlude: My Favorite Vocalists


Mariah Carey (featuring Snoop Dogg), "Crybaby"